Publication 2025

432.

Yu YL, An DW, Chori BS, Kaleta BP, Mokwatsi G, Martens DS, Abiodun OO, Anya T, Łebek-Szatańska A, Yeh JS, Mels CMC, Latosinska A, Kruger R, Isiguzo G, Narkiewicz K, Shehu MN, Salazar M, Espeche W, Mujaj B, Brgulian-Hitij J, Olszanecka A, Wojciechowska W, Reyskens P, Rajzer M, Januszewicz A, Stolarz-Skrzypek K, Asayama K, Allegaert K, Verhamme P, Mischak H, Nawrot TS, Odili AN, Staessen JA; the UPRIGHT-HTM investigators.

Racial and regional disparities in the risk of noncommunicable disease between sub-Saharan black and European white patients.

J Hypertens. 2025 Mar 1;43(3):481-491. doi: 10.1097/HJH.0000000000003930. Epub 2024 Nov 21.

View Abstract      Request Reprint

431.

Mischak H, Schanstra JP, Vlahou A, Beige J.

Clinical Proteomics, Quo Vadis?

Proteomics 2025 Feb 9:e202400346. doi: 10.1002/pmic.202400346.

View Abstract      Request Reprint

430.

Aktas G, Keller F, Siwy J, Latosinska A, Mischak H, Mayor J, Clausen J, Wilhelmi M, Brauckmann V, Sehmisch S, Pacha TO.

Application of urinary peptide-biomarkers in trauma patients as a predictive tool for prognostic assessment, treatment and intervention timing.

Sci Rep. 2025 Jan 6;15(1):898. doi: 10.1038/s41598-024-83878-3.

View Abstract      Request Reprint

429.

Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, Frimodt-Møller M, Mischak H, von der Leyen H, Hansen TW, Kümler T, Persson F, Rossing P; PRIORITY Study group.

Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.

Diabetes Obes Metab. 2025 Jan;27(1):387-393. doi: 10.1111/dom.16037. Epub 2024 Oct 28.

View Abstract      Request Reprint